Literature DB >> 10333412

Improvement in the intestinal processes of hydroelectrolytic absorption and secretion in abdominal pathologies of surgical interest treated with SMS 201-995: experimental protocol.

F F Guiró1, G Bertolini, J V Salas.   

Abstract

The hypothesis that octreotide can improve the intestinal absorption and secretion processes in a mixed group of intestinal pathologies, and that this effect varies according to the pathology in question, was tested. One hundred and twenty Wistar rats were randomly assigned to six pathology groups consisting of three intestinal occlusions including (1) complete, (2) partial, and (3) complete with strangulation, and three mesenteric vascular occlusions including (4) partial permanent, (5) total permanent, and (6) total temporary. Each group contained ten control and ten treated rats. The treated animals received octreotide (100 microg/kg body weight) while the controls were given the same quantity of saline solution every 8 h. After the observation period, the contents of the small intestine were extracted and its volume measured before and after centrifugation; the concentration and total content of Na, K, Cl, and bicarbonate was then analyzed. Samples of all the intestines at specific distances from the lesion zone were treated and stained, and then evaluated according to a specific score to quantify the lesions. The concentration and contents of electrolytes in the intestine and its volume (before and after centrifugation) were lower in the treated animals, but varied according to the pathology. There was a nonadditive influence between the type of pathology and treatment for the four electrolytes and intestinal volume. The effects of the drug make it directly or indirectly possible to decrease the intestinal lesions to improve the absorption-secretion processes. Octreotide acts on intestinal secretion and absorption in all the pathologies analyzed except for total permanent intestinal ischemia. Its action also varies according to the type of pathology involved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10333412     DOI: 10.1007/BF02483033

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  25 in total

1.  Studies on small intestinal obstruction. IV. Circulatiory effects of artificial small bowel distension after obstruction.

Authors:  U Ohman
Journal:  Acta Chir Scand       Date:  1975

Review 2.  Somatostatin and octreotide in gastroenterology.

Authors:  A K Burroughs; P A McCormick
Journal:  Aliment Pharmacol Ther       Date:  1991-08       Impact factor: 8.171

Review 3.  Octreotide: a synthetic analog of somatostatin.

Authors:  J M Rosenberg
Journal:  Drug Intell Clin Pharm       Date:  1988-10

4.  Effects of intraluminal pressure on regional blood flow in obstructed and unobstructed small intestines in the rat.

Authors:  L Enochsson; G Nylander; U Ohman
Journal:  Am J Surg       Date:  1982-11       Impact factor: 2.565

5.  Bacterial microflora, endogenous endotoxin, and prostaglandins in small bowel obstruction.

Authors:  R Roscher; W Oettinger; H G Beger
Journal:  Am J Surg       Date:  1988-02       Impact factor: 2.565

6.  Somatostatin analogue inhibits intestinal regeneration.

Authors:  J S Thompson; B L Nguyen; R F Harty
Journal:  Arch Surg       Date:  1993-04

Review 7.  Pharmacodynamic effects of Sandostatin in the gastrointestinal tract.

Authors:  K E Gyr; R Meier
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

8.  Somatostatin analogues suppress the inflammatory reaction in vivo.

Authors:  K Karalis; G Mastorakos; G P Chrousos; G Tolis
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 9.  Physiological role of somatostatin in the digestive tract: gastric acid secretion, intestinal absorption, and motility.

Authors:  G J Krejs
Journal:  Scand J Gastroenterol Suppl       Date:  1986

10.  The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis.

Authors:  J Wahren; L S Eriksson
Journal:  Scand J Gastroenterol Suppl       Date:  1986
View more
  1 in total

1.  Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.

Authors:  Takuya Shinjo; Ryogo Kagami
Journal:  Support Care Cancer       Date:  2009-03-11       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.